Immunotherapy Charts New Course for Resectable NSCLC Treatment

Three cycles of neoadjuvant nivolumab plus chemotherapy improved long-term clinical outcomes in patients with resectable stage IB-IIIA NSCLC.
Medscape Medical News

Leave a Reply

Your email address will not be published.